Ensysce Biosciences (NASDAQ:ENSC) Raised to Hold at Wall Street Zen

Ensysce Biosciences (NASDAQ:ENSC) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ensysce Biosciences in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Ensysce Biosciences Stock Performance

Shares of Ensysce Biosciences stock opened at $0.52 on Friday. The business has a 50-day moving average price of $0.29 and a two-hundred day moving average price of $0.42. Ensysce Biosciences has a 1-year low of $0.23 and a 1-year high of $2.75. The company has a market cap of $8.00 million, a P/E ratio of -0.16 and a beta of 0.84.

Ensysce Biosciences (NASDAQ:ENSC) last issued its earnings results on Friday, May 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.21. The business had revenue of $0.96 million for the quarter, compared to analyst estimates of $1.00 million. Ensysce Biosciences had a negative net margin of 250.39% and a negative return on equity of 766.45%. Equities research analysts forecast that Ensysce Biosciences will post -1.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Ensysce Biosciences

Large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in Ensysce Biosciences during the 3rd quarter valued at about $34,000. Virtu Financial LLC bought a new stake in Ensysce Biosciences during the 3rd quarter worth approximately $34,000. DRW Securities LLC raised its stake in shares of Ensysce Biosciences by 42.4% in the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock worth $91,000 after purchasing an additional 29,336 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its stake in shares of Ensysce Biosciences by 100.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after purchasing an additional 75,000 shares during the last quarter. Institutional investors own 5.63% of the company’s stock.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.